The association between 5-HT1A binding and temporal lobe epilepsy: A meta-analysis of molecular imaging studies

Cai, Lun; Zhang, Xu; Luo, Huazheng; He, Qianchao; Diao, Limei; Gui, Xiongbin; Wei, Liping

doi:10.1016/j.yebeh.2023.109354

Cited by 3 publications

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A decrease in serotonergic receptors in the dental gyrus, may support the establishment of an excitatory/inhibitory imbalance in the trisynaptic circuit that underlies the neuropathology of epilepsy generation. A recent investigation in humans revealed a significant reduction in 5‐HT 1A binding in the hippocampus, temporal cortex, amygdaloid complex and frontal lobe in patients with temporal lobe epilepsy 174 . Interestingly, there is evidence that downregulation of postsynaptic 5‐HT 1A receptors may exacerbate the severity of epilepsy‐associated depression 175 .…”

Section: Introductionmentioning

confidence: 99%

Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

de Fátima dos Santos Sampaio,

de Paiva,

Sampaio

et al. 2024

Basic Clin Pharma Tox

View full text Add to dashboard Cite

Studies have demonstrated the neuroprotective effect of cannabidiol (CBD) and other Cannabis sativa L. derivatives on diseases of the central nervous system caused by their direct or indirect interaction with endocannabinoid system‐related receptors and other molecular targets, such as the 5‐HT1A receptor, which is a potential pharmacological target of CBD. Interestingly, CBD binding with the 5‐HT1A receptor may be suitable for the treatment of epilepsies, parkinsonian syndromes and amyotrophic lateral sclerosis, in which the 5‐HT1A serotonergic receptor plays a key role. The aim of this review was to provide an overview of cannabinoid effects on neurological disorders, such as epilepsy, multiple sclerosis and Parkinson's diseases, and discuss their possible mechanism of action, highlighting interactions with molecular targets and the potential neuroprotective effects of phytocannabinoids. CBD has been shown to have significant therapeutic effects on epilepsy and Parkinson's disease, while nabiximols contribute to a reduction in spasticity and are a frequent option for the treatment of multiple sclerosis. Although there are multiple theories on the therapeutic potential of cannabinoids for neurological disorders, substantially greater progress in the search for strong scientific evidence of their pharmacological effectiveness is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

de Fátima dos Santos Sampaio,

de Paiva,

Sampaio

et al. 2024

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Dourron,

Nichols,

Simonsson

et al. 2023

Psychopharmacology

View full text Add to dashboard Cite

Alzheimer’s Disease and Epilepsy: Exploring Shared Pathways and Promising Biomarkers for Future Treatments

Kalyvas,

Dimitriou,

Ioannidis

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Alzheimer’s disease (AD) and epilepsy represent two complex neurological disorders with distinct clinical manifestations, yet recent research has highlighted their intricate interplay. This review examines the association between AD and epilepsy, with particular emphasis on late-onset epilepsy of unknown etiology, increasingly acknowledged as a prodrome of AD. It delves into epidemiology, pathogenic mechanisms, clinical features, diagnostic characteristics, treatment strategies, and emerging biomarkers to provide a comprehensive understanding of this relationship. Methods: A comprehensive literature search was conducted, identifying 128 relevant articles published between 2018 and 2024. Results: Findings underscore a bidirectional relationship between AD and epilepsy, indicating shared pathogenic pathways that extend beyond traditional amyloid-beta and Tau protein pathology. These pathways encompass neuroinflammation, synaptic dysfunction, structural and network alterations, as well as molecular mechanisms. Notably, epileptic activity in AD patients may exacerbate cognitive decline, necessitating prompt detection and treatment. Novel biomarkers, such as subclinical epileptiform activity detected via advanced electroencephalographic techniques, offer promise for early diagnosis and targeted interventions. Furthermore, emerging therapeutic approaches targeting shared pathogenic mechanisms hold potential for disease modification in both AD and epilepsy. Conclusions: This review highlights the importance of understanding the relationship between AD and epilepsy, providing insights into future research directions. Clinical data and diagnostic methods are also reviewed, enabling clinicians to implement more effective treatment strategies.

show abstract

The association between 5-HT1A binding and temporal lobe epilepsy: A meta-analysis of molecular imaging studies

Cited by 3 publications

References 61 publications

Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?

Alzheimer’s Disease and Epilepsy: Exploring Shared Pathways and Promising Biomarkers for Future Treatments

Contact Info

Product

Resources

About